Why Shares in Arcutis Biotherapeutics Surged Again This Week

Arcutis Biotherapeutics shares rose 9.3% this week (about +96% year-to-date in 2025) after the FDA accepted a supplemental NDA for Zoryve (roflumilast) cream 0.3% to treat plaque psoriasis in children aged 2–5, with a target review completion date of June 29, 2026. The filing complements existing approvals for Zoryve cream 0.3% in children 6+ and Zoryve 0.05% for ages 2–5 with atopic dermatitis, and, together with a recent third-quarter sales report and management guidance that beat estimates, strengthens confidence in Arcutis’s ability to expand Zoryve’s label and commercial opportunity. If approved and successfully commercialized, the sNDA would materially broaden pediatric indications and support further upside to the company’s valuation.

Analysis

Arcutis Biotherapeutics shares climbed 9.3% in the latest week and are up roughly 96% year-to-date in 2025 after the FDA accepted a supplemental NDA for Zoryve (roflumilast) cream 0.3% to treat plaque psoriasis in children aged two to five. The FDA has set a target review completion date of June 29, 2026, making this a multi-quarter regulatory catalyst that could meaningfully expand the pediatric label if approved.

Zoryve is already approved in multiple formulations and concentrations — cream 0.3% for children six and older, foam for hair-bearing areas, and cream 0.05% for ages two to five with atopic dermatitis — so the sNDA specifically extends the 0.3% cream into a younger plaque psoriasis cohort and could increase addressable market and lifetime product value. The acceptance complements recent third-quarter results and management guidance that materially beat market estimates, reinforcing confidence in near-term commercial execution.

Market signals are moderately positive (sentiment score ~0.55, ARQT-specific 0.6) but the market impact score is modest (0.45), reflecting that upside depends on a regulatory approval and subsequent commercialization. Key risks include the binary FDA outcome, the long review timeline to June 2026, and the need to convert label expansion into sustained sales growth against elevated share price performance.

Key Decisions for Investors

• Consider a tactical increase in exposure to ARQT on the back of sNDA acceptance and strong Q3 guidance, but size positions to reflect the binary regulatory risk and the June 29, 2026 review timeline
• Existing holders should hold and monitor interim regulatory updates and quarterly sales vs. management guidance closely, as successful commercialization of an expanded pediatric label is the primary driver of further upside
• Given the 96% YTD run and moderate market-impact signal, implement downside protection such as options hedges or partial profit-taking to lock in gains if you are risk-sensitive